Friday, 16 October 2026European Markets

MicroPower Stock Soars 12%: End Of Session Boosts ENSURGE Performance

Loading stream...

(VIANEWS) - At 15:56 EST on Friday, shares of ENSURGE MICROPOWER (ENSU.OL) surged 12.17% to close at kr0.13 following two consecutive gains, and five sessions in which it advanced. This trend indicates positive trading today. ENSURGE MICROPOWER's previous close was at kr0.12, 97.26% below its 52-week high of kr4.19.

About ENSURGE MICROPOWER

Ensurge Micropower ASA specializes in the production and sale of ultrathin energy storage solutions powered by its advanced solid-state lithium battery technology. Their products provide rechargeable solutions for wearable devices, connected sensors and other applications requiring rechargeable battery solutions. Originally known as Thin Film Electronics ASA, Ensurge Micropower was established in 2005 in Oslo Norway as a subsidiary.

Yearly Analysis

Based on available data, ENSURGE MICROPOWER's stock has seen significant value decline over the last year; currently trading at around Kr0.13, which is significantly below both its 52-week high of Kr4.19 and low of Kr0.10. This indicates a sharp falloff. ENSURGE MICROPOWER has an EBITDA value of -150.46, signifying negative earnings before taxes, depreciation, amortization and interest - suggesting it may currently be operating at a loss and therefore may not represent an attractive investment at present. Overall, investors should proceed with caution when considering investing in ENSURGE MICROPOWER as its current valuation and negative earnings suggest the company may be facing financial challenges. Therefore, further investigation and analysis may be beneficial prior to making a final investment decision.

Technical Analysis

ENSURGE MICROPOWER's stock price is trading above its 50-day moving average of kr0.12, yet significantly below its 200-day moving average of kr0.76 - this suggests that it has experienced short-term decline while exhibiting stability over longer time frames. Today's trading volume for this stock was 74.08% higher than its average volume of 12139800, suggesting increased trading activity. This could be seen as positive news as increased trading activity often indicates greater interest for an individual stock. ENSURGE MICROPOWER's volatility has been relatively low over the past week, month, and quarter. The stock's highest average weekly and monthly amplitudes of volatility was 2.09% in each instance (2.09% for week; 7.15 for month; and 5.22% for quarter). According to the stochastic oscillator, an indicator for overbought and oversold conditions, ENSURGE MICROPOWER's stock is currently oversold (=20), suggesting it may be undervalued and poised for potential rebound in the near future.

Equity Analysis

Based on the available information, ENSURGE MICROPOWER has an earnings per share (EPS) value of kr-1.02. This indicates a loss per share since last year; however, investors should remember that an EPS is only an historical figure and may not accurately represent future earnings potential of the company. Investors should take other factors such as revenue growth, industry trends, and competitive landscape into account before making investment decisions.

More news about ENSURGE MICROPOWER (ENSU.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com